{
  "company": "Pfizer",
  "data_source": "https://www.pfizer.com/science/drug-product-pipeline",
  "extraction_date": "2025-07-03",
  "pipeline_overview": {
    "description": "We're in relentless pursuit of medicines and vaccines that will benefit patients around the world. Our ambitions are big and our product pipeline has never been stronger.",
    "areas_of_focus": [
      "Inflammation & Immunology",
      "Internal Medicine", 
      "Oncology",
      "Vaccines"
    ],
    "development_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3", 
      "Registration"
    ],
    "submission_types": [
      "New Molecular Entity",
      "Product Enhancement"
    ],
    "compound_types": [
      "Biologic",
      "Small Molecule",
      "Vaccine"
    ]
  },
  "pipeline_statistics": {
    "total_candidates": 108,
    "phase_1": 47,
    "phase_2": 28,
    "phase_3": 30,
    "registration": 3
  },
  "sample_pipeline_candidates": {
    "phase_1": [
      {
        "name": "ABRYSVO",
        "indication": "Respiratory Syncytial Virus Infection (pediatric)",
        "area_of_focus": "Vaccines",
        "submission_type": "Product Enhancement",
        "compound_type": "Vaccine",
        "status": "Current"
      },
      {
        "name": "CTB+AVP (PF-07612577)",
        "indication": "Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis (FAST TRACK - U.S.)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      },
      {
        "name": "Dekavil",
        "indication": "Rheumatoid Arthritis (Biologic)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      },
      {
        "name": "felmetatug vedotin (PF-08046048) (B7H4V)",
        "indication": "Advanced Solid Tumors (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      },
      {
        "name": "PADCEV (enfortumab vedotin)",
        "indication": "BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "Product Enhancement",
        "compound_type": "Biologic",
        "status": "Current"
      },
      {
        "name": "PF-06414300",
        "indication": "Ulcerative Colitis",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      },
      {
        "name": "PF-06835375",
        "indication": "Lupus (Biologic)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "Product Enhancement",
        "compound_type": "Biologic",
        "status": "Current"
      },
      {
        "name": "PF-06940434",
        "indication": "Advanced Solid Tumors (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      },
      {
        "name": "PF-06954522",
        "indication": "Chronic Weight Management",
        "area_of_focus": "Internal Medicine",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      },
      {
        "name": "PF-07054894",
        "indication": "Inflammatory Bowel Disease",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      }
    ]
  },
  "development_phase_definitions": {
    "phase_1": {
      "description": "Phase 1 asks the questions 'Is an investigational drug or vaccine safe?' and 'What is the correct dose?' Typically, these studies are done with a small group of healthy volunteers.",
      "success_rate": "Only 10% of Phase 1 candidates will make it to approval industry-wide",
      "timeline": "On average, it takes 10 years to move from Phase 1 to regulatory approval"
    },
    "phase_2": {
      "description": "Phase 2 asks the questions 'Does this investigational medicine or vaccine work in the disease that's targeted?' and 'Are there any side effects that may occur?'",
      "participants": "Several hundred participants who have the condition",
      "duration": "Several months to a few years",
      "failure_rate": "70% of Phase 2 candidates industry-wide fail in this stage"
    },
    "phase_3": {
      "description": "Phase 3 studies seek to find out how safe and effective the investigational drug or vaccine is for people with the condition, and also if it works compared to a placebo or something else currently available",
      "timeline": "Usually signifies when an investigational medicine or vaccine may be two to three years from approval"
    },
    "registration": {
      "description": "After Phase 3, if the clinical trial data supports it, an extensive data package is submitted to the U.S. Food and Drug Administration (FDA) and other regulatory authorities for review",
      "review_time": "This review process typically takes a year"
    }
  },
  "regulatory_designations": {
    "fast_track": "A designation available to a product if it is intended for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs",
    "breakthrough_designation": "May be granted to a drug intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates substantial improvement over existing therapies",
    "orphan_drug": "Status may be granted to drugs intended for rare diseases/disorders that affect fewer than 200,000 people in the U.S.",
    "priority_review": "A U.S. drug application will receive priority review if it treats a serious condition and would provide significant improvement in safety or effectiveness"
  },
  "last_updated": "April 29, 2025"
}
